| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/12/2001 | WO2001025438A2 Ifn-alpha homologues |
| 04/12/2001 | WO2001025437A2 Growth factor polypeptides and nucleic acids encoding same |
| 04/12/2001 | WO2001025436A2 Endozepine-like polypeptides and polynucleotides encoding same |
| 04/12/2001 | WO2001025434A1 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 04/12/2001 | WO2001025433A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 04/12/2001 | WO2001025422A2 Antisense compositions and cancer-treatment methods |
| 04/12/2001 | WO2001025419A1 ALTERING GENE EXPRESSION WITH ssDNA PRODUCED IN VIVO |
| 04/12/2001 | WO2001025408A1 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 04/12/2001 | WO2001025404A1 Methods for inhibiting osteoclast formation or methods for inhibiting bone resorption |
| 04/12/2001 | WO2001025398A2 Process for inducing functional tolerance to gene transfer products |
| 04/12/2001 | WO2001025291A1 Sugar binding polymers and the use thereof |
| 04/12/2001 | WO2001025271A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | WO2001025269A2 Human g-protein coupled receptor |
| 04/12/2001 | WO2001025252A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | WO2001025248A2 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | WO2001025242A1 Novel thiazolo(4,5-d)pyrimidine compounds |
| 04/12/2001 | WO2001025240A1 HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR |
| 04/12/2001 | WO2001025239A2 Oxazinoquinolones useful for the treatment of viral infections |
| 04/12/2001 | WO2001025238A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 04/12/2001 | WO2001025237A1 Novel imidazopyridine carbonitrile compounds |
| 04/12/2001 | WO2001025232A1 Process for the preparation of paroxetine hydrochloride acetone solvate |
| 04/12/2001 | WO2001025230A1 Process for the preparation of paroxetine hydrochloride acetone solvate |
| 04/12/2001 | WO2001025229A1 Amide compounds |
| 04/12/2001 | WO2001025228A1 Amine derivatives |
| 04/12/2001 | WO2001025227A2 Quinolyl propyl piperidine derivatives and their use as antibacterial agents |
| 04/12/2001 | WO2001025226A1 Dithiolane derivatives |
| 04/12/2001 | WO2001025220A1 Triazine kinase inhibitors |
| 04/12/2001 | WO2001025219A2 Piperazine compounds |
| 04/12/2001 | WO2001025217A1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 04/12/2001 | WO2001025213A2 Pyrrolo imidazole derivatives and their use as medicaments |
| 04/12/2001 | WO2001025210A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands |
| 04/12/2001 | WO2001025209A1 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
| 04/12/2001 | WO2001025208A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 04/12/2001 | WO2001025207A1 Novel nicotinonitrile compounds |
| 04/12/2001 | WO2001025204A1 Novel trisubstituted pyridine compounds |
| 04/12/2001 | WO2001025200A1 Cyclic amine compounds as ccr5 antagonists |
| 04/12/2001 | WO2001025198A1 Method for improving the solubility of tricyclic amino alcohol derivatives |
| 04/12/2001 | WO2001025197A1 Antifungal enediynes |
| 04/12/2001 | WO2001025192A1 Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| 04/12/2001 | WO2001025189A1 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds |
| 04/12/2001 | WO2001025188A1 Novel carbamates and ureas |
| 04/12/2001 | WO2001025187A2 Benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides |
| 04/12/2001 | WO2001025186A1 Novel ltb4 antagonist, method for the production thereof and its use as a medicament |
| 04/12/2001 | WO2001024866A1 System and device for preventing restenosis in body vessels |
| 04/12/2001 | WO2001024842A2 Hybrid matrices and hybrid matrix mixtures |
| 04/12/2001 | WO2001024831A2 Polymer stabilized neuropeptides |
| 04/12/2001 | WO2001024826A2 Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens |
| 04/12/2001 | WO2001024824A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 04/12/2001 | WO2001024804A2 Method for preparing a composition by mother-of-pearl extraction, and use thereof in cosmetics and dermatology |
| 04/12/2001 | WO2001024803A2 Pharmaceutical compositions containing copper, salicylic acid and vitamines c |
| 04/12/2001 | WO2001024802A1 Antiobestic agents |
| 04/12/2001 | WO2001024801A1 Pharmaceutical formulations containing poorly soluble drug substances |
| 04/12/2001 | WO2001024800A1 Erection insufficiency remedies |
| 04/12/2001 | WO2001024799A1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 04/12/2001 | WO2001024798A1 Use of central cannabinoid receptor antagonist for preparing medicines |
| 04/12/2001 | WO2001024797A1 Integrin receptor antagonists |
| 04/12/2001 | WO2001024796A1 1,2,4-triazole derivatives, composition, process of making and methods of use |
| 04/12/2001 | WO2001024795A1 RETARD FORM CONTAINING α-LIPOIC ACID (DERIVATIVES) |
| 04/12/2001 | WO2001024794A1 A method for the treatment of ocular oxidative stress |
| 04/12/2001 | WO2001024793A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 04/12/2001 | WO2001024792A1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 04/12/2001 | WO2001024791A1 Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders |
| 04/12/2001 | WO2001024790A1 Agents for relieving carbonyl stress |
| 04/12/2001 | WO2001024789A1 Agents for reducing cholesterol-uptake and liquid-uptake |
| 04/12/2001 | WO2001024788A2 Treating endometriosis or infertility, or improving fertility |
| 04/12/2001 | WO2001024787A1 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| 04/12/2001 | WO2001024786A1 Preventive or therapeutic drugs for diabetes |
| 04/12/2001 | WO2001024785A2 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 04/12/2001 | WO2001024784A2 New use |
| 04/12/2001 | WO2001024783A2 Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence |
| 04/12/2001 | WO2001024782A2 Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
| 04/12/2001 | WO2001024781A2 Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| 04/12/2001 | WO2001024780A2 Soft gel capsule resistant to gastric juices |
| 04/12/2001 | WO2001024778A1 Anti-inflammatory pharmaceutical formulations |
| 04/12/2001 | WO2001024777A1 Coated solid dosage forms |
| 04/12/2001 | WO2001024774A1 Ortho ester lipids |
| 04/12/2001 | WO2001024772A1 Formulation for menopausal women |
| 04/12/2001 | WO2001024769A1 Antimicrobial perfuming compositions |
| 04/12/2001 | WO2001024764A2 Cell targeting compositions and methods of using the same |
| 04/12/2001 | WO2001024763A2 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 04/12/2001 | WO2001024645A1 Nutritional composition |
| 04/12/2001 | WO2001024636A1 Process for improving human and animal health |
| 04/12/2001 | WO2001024634A1 Active ingredient combinations having insecticidal and acaricidal properties |
| 04/12/2001 | WO2001005382A8 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 04/12/2001 | WO2000077190A3 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 04/12/2001 | WO2000076958A3 Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| 04/12/2001 | WO2000069426A3 Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders |
| 04/12/2001 | WO2000064454A3 Pharmaceutical composition comprising an inositol and a metal ion for improving insulin sensitivity and glucose metabolism |
| 04/12/2001 | WO2000061755A3 Secreted human proteins |
| 04/12/2001 | WO2000056333A8 Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
| 04/12/2001 | WO2000056316A8 Treatment of gallstones |
| 04/12/2001 | WO2000056304A3 Anti-inflammatory uses of manzamines |
| 04/12/2001 | WO2000053182A3 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis |
| 04/12/2001 | WO2000053165A3 Use of inhibitors of endotoxin for the treatment of chachexia |
| 04/12/2001 | WO2000049992A3 USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS |
| 04/12/2001 | WO2000048582A3 Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence |
| 04/12/2001 | WO2000047192A3 UBIQUINONE QnFOR THE TREATMENT OF PAINS |
| 04/12/2001 | WO2000045805A3 Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates |
| 04/12/2001 | WO2000004891A3 Anti-ulcer composition |
| 04/12/2001 | WO1999067283A3 Two-kinase domain mitogen- and stress-activated protein kinases and uses thereof |